title: Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.
abstract: Twenty-eight myelodysplastic syndromes (MDS) patients were treated with arsenic trioxide (ATO) and thalidomide. Seven patients responded including one complete hematologic and cytogenetic response and one with regression in spleen size. Two trilineage responses were seen in patients with inv(3)(q21q26.2). Three of five patients who had high pre-therapy EVI1 levels showed unexpectedly good responses while two died early in the first cycle. In vitro studies using 32Dcl3 cells forced to express EVI1 confirmed increased sensitivity of these cells to ATO. Both low/high risk MDS may benefit significantly from therapy with ATO/thalidomide, and those with high pre-therapy EVI1 expression may be uniquely sensitive.
authors.affiliation: Section of Myeloid Diseases and MDS Center, Rush University, Rush-Presbyterian-St. Luke's Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612-3515, USA. azra_raza@rush.edu
authors.forename: Azra
authors.initials: A
authors.lastname: Raza
authors.forename: Silvia
authors.initials: S
authors.lastname: Buonamici
authors.forename: Laurie
authors.initials: L
authors.lastname: Lisak
authors.forename: Sarah
authors.initials: S
authors.lastname: Tahir
authors.forename: Donglan
authors.initials: D
authors.lastname: Li
authors.forename: Mehnaz
authors.initials: M
authors.lastname: Imran
authors.forename: Nusrat Ijaz
authors.initials: NI
authors.lastname: Chaudary
authors.forename: Hassan
authors.initials: H
authors.lastname: Pervaiz
authors.forename: J Alejandro
authors.initials: JA
authors.lastname: Gallegos
authors.forename: M Imran
authors.initials: MI
authors.lastname: Alvi
authors.forename: Muhammad
authors.initials: M
authors.lastname: Mumtaz
authors.forename: Sefer
authors.initials: S
authors.lastname: Gezer
authors.forename: Parameswaran
authors.initials: P
authors.lastname: Venugopal
authors.forename: Poluru
authors.initials: P
authors.lastname: Reddy
authors.forename: Naomi
authors.initials: N
authors.lastname: Galili
authors.forename: Anna
authors.initials: A
authors.lastname: Candoni
authors.forename: Jack
authors.initials: J
authors.lastname: Singer
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Nucifora
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D019070:Cell Lineage; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000074008:MDS1 and EVI1 Complex Locus Protein; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000473:pathology; D010087:Oxides / Q000627:therapeutic use*; D011519:Proto-Oncogenes; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D013154:Spleen / Q000378:metabolism / Q000473:pathology; D013792:Thalidomide / Q000627:therapeutic use*; D014157:Transcription Factors; D016335:Zinc Fingers
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D004268:DNA-Binding Proteins; D007166:Immunosuppressive Agents; D000074008:MDS1 and EVI1 Complex Locus Protein; C063575:MECOM protein, human; D010087:Oxides; D014157:Transcription Factors; D013792:Thalidomide; D000077237:Arsenic Trioxide